Criticism mounts of India's 'abrupt' approval for Bharat Biotech's Covaxin

The recommendations of the Indian drugs regulator's subject expert committee (SEC) released on Tuesday show that the panel asked Bharat Biotech International Ltd to present more efficacy data for its COVID-19 shot before it could consider approving the treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2XeHnMT
via IFTTT